阿帕替尼在肺癌研究中的进展

Research progress of Apatinib in lung cancer

肺癌是癌症相关死亡的最常见原因。目前临床治疗肺癌方法主要包括手术、放化疗、靶向和免疫等综合治疗,虽然经过系统治疗后患者生存期得到改善,但仍容易复发或耐药,因此,寻求新的、高效的治疗肺癌的药物和方法乃当务之急。阿帕替尼是一种对血管内皮细胞生长因子2具有高度选择性的抗血管生成药物,已于2014年10月被我国食品药物管理局批准用于治疗晚期或转移性胃癌的一线方案,此外,大量研究表明,包括肺癌在内的多种实体瘤中,阿帕替尼表现出显著的抗肿瘤活性和可耐受的毒性。本文综述了近年来阿帕替尼抗肺癌作用机制的研究进展,包括抑制增殖和迁移、阻滞细胞周期、调控凋亡途径、逆转耐药、化疗、放疗增敏调节免疫、抑制肿瘤干细胞。为肺癌治疗提供新思路。

Lung cancer is the most common cause of cancer-related death in the world,the treatment options for lung cancer include a combination of surgery,chemotherapy,targeted therapy,and immunotherapy.Although the survival of patients has been improved after systemic treatment,they are still prone to recurrence or drug resistance.Therefore,innovating novel and efficient drugs for lung cancer have became urgent matters.Apatinib is a highly selective anti-angiogenesis-targeted agents for vascular endothelial growth factor receptor 2(VEGFR2),and it has been approved by China Food and Drug Administration(CFDA)in October 2014 as a first-line regimen for advanced or metastatic gastric cancer.In addition,a large number of studies have shown that Apatinib has significant anti-tumor activity and tolerability in multiple tumour types including lung cancer.The advances of Apatinib in lung cancer,including inhibition of proliferation and migration,arrest of cell cycle,regulation of apoptosis pathway,reversal of drug resistance,sensitization of chemotherapy and radiotherapy,regulation of immunity,and inhibition of tumor stem cells,aiming to provide new ideas for the treatment of lung cancer.